ANIP

insider transactions

ANI PHARMACEUTICALS INC — buys & sells by directors, officers and 10% owners (SEC Form 4).

30D 90D 1Y

Net shares · 365d

-132.7K

0 buy · 132.7K sell

Net value · 365d

-$10.2M

$0 in · $10.2M out

Sentiment · 365d

Net selling

0% buying · 100% selling

Open-market trades · 365d

0 buy · 132.7K sell

Net buy / sell volume

Tap or hover the chart for daily net volume. Green = net buying, red = net selling.

All transactions

Sell·S
Jun 12, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$41.0K

500 sh · $82.03

Own -1%
Sell·S
Jun 8, 26

Thomas Haughey

Director · 10b5-1

$161.8K

2.0K sh · $80.88

Own -5%
Exercise·M
Jun 5, 26

Stephen P. Carey KEY

SVP & CFO · 10b5-1

$164.0K

3.3K sh · $49.51

Own +100%
Sell·S
Jun 5, 26

Stephen P. Carey KEY

SVP & CFO · 10b5-1

$265.0K

3.3K sh · $80.00

Own -2%
Exercise·M
Jun 5, 26

Stephen P. Carey KEY

SVP & CFO · 10b5-1

$164.0K

3.3K sh · $49.51

Own +2%
Grant·A
May 21, 26

Jeanne Thoma

Director

$0

4.4K sh

Own +19%
Grant·A
May 21, 26

Matthew J Leonard

Director

$0

4.4K sh

Own +63%
Grant·A
May 21, 26

Antonio R Pera

Director

$0

4.4K sh

Own +19%
Grant·A
May 21, 26

Renee P Tannenbaum

Director

$0

4.4K sh

Own +17%
Grant·A
May 21, 26

Thomas Haughey

Director · 10b5-1

$0

4.4K sh

Own +12%
Sell·S
May 13, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$39.1K

500 sh · $78.16

Own -1%
Sell·S
May 13, 26

Patrick D Walsh

Director

$806.3K

10.0K sh · $80.63

Own -21%
Sell·S
May 12, 26

Ori Gutwerg

SVP, GENERICS

$220.4K

2.8K sh · $79.50

Own -3%
Sell·S
May 12, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$36.4K

459 sh · $79.21

Own -1%
Sell·S
May 11, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$4.3M

55.0K sh · $77.57

Own -14%
Sell·S
May 11, 26

Patrick D Walsh

Director

$320.8K

4.0K sh · $80.75

Own -8%
Sell·S
Apr 13, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$39.0K

500 sh · $77.95

Own -1%
Sell·S
Mar 13, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$36.3K

500 sh · $72.62

Own -1%
Sell·S
Mar 13, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$226.5K

3.2K sh · $71.64

Own -3%
Sell·S
Mar 11, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$357.5K

4.8K sh · $74.91

Own -11%
Sell·S
Mar 9, 26

Krista Davis

SVP, CHIEF HR OFFICER · 10b5-1

$377.1K

5.1K sh · $74.13

Own -9%
Sell·S
Mar 9, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$267.2K

3.6K sh · $74.18

Own -4%
Other·F
Mar 7, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$245.4K

3.3K sh · $74.04

Own -3%
Other·F
Mar 7, 26

Ori Gutwerg

SVP, GENERICS

$245.4K

3.3K sh · $74.04

Own -4%
Other·F
Mar 7, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$1.3M

17.1K sh · $74.04

Own -4%
Other·F
Mar 7, 26

Stephen P. Carey KEY

SVP & CFO

$381.3K

5.2K sh · $74.04

Own -3%
Sell·S
Mar 6, 26

Krista Davis

SVP, CHIEF HR OFFICER · 10b5-1

$111.4K

1.5K sh · $75.00

Own -3%
Sell·S
Mar 6, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$157.4K

2.1K sh · $74.22

Own -2%
Exercise·M
Mar 5, 26

Stephen P. Carey KEY

SVP & CFO

$164.0K

3.3K sh · $49.51

Own +50%
Sell·S
Mar 5, 26

Stephen P. Carey KEY

SVP & CFO

$302.2K

4.0K sh · $75.56

Own -2%
Sell·S
Mar 5, 26

Stephen P. Carey KEY

SVP & CFO

$249.8K

3.3K sh · $75.42

Own -2%
Exercise·M
Mar 5, 26

Stephen P. Carey KEY

SVP & CFO

$164.0K

3.3K sh · $49.51

Own +2%
Sell·S
Mar 3, 26

Patrick D Walsh

Director

$445.4K

6.0K sh · $74.23

Own -10%
Sell·S
Mar 3, 26

Ori Gutwerg

SVP, GENERICS

$157.6K

2.1K sh · $76.50

Own -2%
Sell·S
Mar 2, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$30.9K

417 sh · $74.00

Own -0%
Other·F
Feb 28, 26

Krista Davis

SVP, CHIEF HR OFFICER

$114.9K

1.6K sh · $73.90

Own -3%
Other·F
Feb 28, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC.

$114.9K

1.6K sh · $73.90

Own -2%
Other·F
Feb 28, 26

Chad Gassert

SVP - CORP. DEV. & STRATEGY

$164.1K

2.2K sh · $73.90

Own -3%
Other·F
Feb 28, 26

Christopher Mutz

HEAD OF RARE DISEASE

$164.1K

2.2K sh · $73.90

Own -2%
Other·F
Feb 28, 26

Ori Gutwerg

SVP, GENERICS

$164.1K

2.2K sh · $73.90

Own -2%
Other·F
Feb 28, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$902.8K

12.2K sh · $73.90

Own -3%
Other·F
Feb 28, 26

Stephen P. Carey KEY

SVP & CFO

$204.9K

2.8K sh · $73.90

Own -1%
Other·F
Feb 28, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$46.4K

628 sh · $73.90

Own -1%
Grant·A
Feb 26, 26

Krista Davis

SVP, CHIEF HR OFFICER

$834.0K

10.8K sh · $77.15

Own +22%
Grant·A
Feb 26, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC.

$1.1M

13.9K sh · $77.15

Own +21%
Grant·A
Feb 26, 26

Chad Gassert

SVP - CORP. DEV. & STRATEGY

$857.6K

11.1K sh · $77.15

Own +17%
Grant·A
Feb 26, 26

Muthusamy Shanmugam

HEAD OF R&D, COO-NOVITIUM OPS

$857.6K

11.1K sh · $77.15

Own +12%
Grant·A
Feb 26, 26

Christopher Mutz

HEAD OF RARE DISEASE

$1.6M

21.3K sh · $77.15

Own +25%
Grant·A
Feb 26, 26

Ori Gutwerg

SVP, GENERICS

$1.0M

13.0K sh · $77.15

Own +17%
Grant·A
Feb 26, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$5.8M

75.6K sh · $77.15

Own +21%
Grant·A
Feb 26, 26

Stephen P. Carey KEY

SVP & CFO

$1.7M

22.2K sh · $77.15

Own +13%
Grant·A
Feb 26, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$464.5K

6.0K sh · $77.15

Own +16%
Sell·S
Feb 20, 26

Krista Davis

SVP, CHIEF HR OFFICER · 10b5-1

$134.9K

1.7K sh · $77.99

Own -3%
Sell·S
Feb 20, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$415.3K

5.3K sh · $78.02

Own -6%
Sell·S
Feb 19, 26

Krista Davis

SVP, CHIEF HR OFFICER · 10b5-1

$161.6K

2.1K sh · $77.53

Own -4%
Other·F
Feb 14, 26

Krista Davis

SVP, CHIEF HR OFFICER

$99.8K

1.3K sh · $77.36

Own -2%
Other·F
Feb 14, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$137.6K

1.8K sh · $77.36

Own -3%
Other·F
Feb 14, 26

Chad Gassert

SVP - CORP. DEV. & STRATEGY

$132.8K

1.7K sh · $77.36

Own -3%
Other·F
Feb 14, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$185.9K

2.4K sh · $77.36

Own -3%
Other·F
Feb 14, 26

Ori Gutwerg

SVP, GENERICS

$146.1K

1.9K sh · $77.36

Own -2%
Other·F
Feb 14, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$796.7K

10.3K sh · $77.36

Own -3%
Other·F
Feb 14, 26

Stephen P. Carey KEY

SVP & CFO

$189.4K

2.4K sh · $77.36

Own -1%
Other·F
Feb 14, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$37.5K

485 sh · $77.36

Own -1%
Sell·S
Feb 13, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$38.4K

500 sh · $76.80

Own -1%
Other·F
Feb 12, 26

Krista Davis

SVP, CHIEF HR OFFICER

$90.5K

1.2K sh · $76.70

Own -2%
Other·F
Feb 12, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$117.7K

1.5K sh · $76.70

Own -2%
Other·F
Feb 12, 26

Chad Gassert

SVP - CORP. DEV. & STRATEGY

$123.3K

1.6K sh · $76.70

Own -2%
Sell·S
Feb 12, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$538.3K

7.0K sh · $76.55

Own -7%
Other·F
Feb 12, 26

Christopher Mutz

HEAD OF RARE DISEASE · 10b5-1

$243.4K

3.2K sh · $76.70

Own -3%
Other·F
Feb 12, 26

Ori Gutwerg

SVP, GENERICS

$136.1K

1.8K sh · $76.70

Own -2%
Other·F
Feb 12, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$896.5K

11.7K sh · $76.70

Own -3%
Other·F
Feb 12, 26

Stephen P. Carey KEY

SVP & CFO

$217.0K

2.8K sh · $76.70

Own -2%
Other·F
Feb 12, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$43.4K

566 sh · $76.70

Own -1%
Other·F
Feb 11, 26

Krista Davis

SVP, CHIEF HR OFFICER

$230.0K

3.0K sh · $76.25

Own -5%
Other·F
Feb 11, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC.

$229.6K

3.0K sh · $76.25

Own -4%
Other·F
Feb 11, 26

Chad Gassert

SVP - CORP. DEV. & STRATEGY

$325.5K

4.3K sh · $76.25

Own -6%
Other·F
Feb 11, 26

Muthusamy Shanmugam

HEAD OF R&D, COO-NOVITIUM OPS

$221.0K

2.9K sh · $76.25

Own -3%
Other·F
Feb 11, 26

Christopher Mutz

HEAD OF RARE DISEASE

$346.6K

4.5K sh · $76.25

Own -4%
Other·F
Feb 11, 26

Ori Gutwerg

SVP, GENERICS

$325.4K

4.3K sh · $76.25

Own -5%
Other·F
Feb 11, 26

Nikhil Lalwani KEY

PRESIDENT & CEO

$2.3M

30.7K sh · $76.25

Own -7%
Other·F
Feb 11, 26

Stephen P. Carey KEY

SVP & CFO

$419.6K

5.5K sh · $76.25

Own -3%
Other·F
Feb 11, 26

Thomas Andrew Rowland

SVP, HEAD - ESTABLISHED BRANDS

$134.4K

1.8K sh · $76.25

Own -4%
Sell·S
Jan 13, 26

Meredith Cook

SR. VP, GENERAL COUNSEL & SEC. · 10b5-1

$42.2K

500 sh · $84.33

Own -1%

Date▾	Insider	Role	Type	Shares	Own Δ	Price	Value
Jun 12, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$82.03	$41.0K
Jun 8, 2026	Thomas Haughey 10b5-1	Director	Sell S	2.0K	-5%	$80.88	$161.8K
Jun 5, 2026	Stephen P. Carey KEY 10b5-1	SVP & CFO	Exercise M	3.3K	+100%	$49.51	$164.0K
Jun 5, 2026	Stephen P. Carey KEY 10b5-1	SVP & CFO	Sell S	3.3K	-2%	$80.00	$265.0K
Jun 5, 2026	Stephen P. Carey KEY 10b5-1	SVP & CFO	Exercise M	3.3K	+2%	$49.51	$164.0K
May 21, 2026	Jeanne Thoma	Director	Grant A	4.4K	+19%	—	$0
May 21, 2026	Matthew J Leonard	Director	Grant A	4.4K	+63%	—	$0
May 21, 2026	Antonio R Pera	Director	Grant A	4.4K	+19%	—	$0
May 21, 2026	Renee P Tannenbaum	Director	Grant A	4.4K	+17%	—	$0
May 21, 2026	Thomas Haughey 10b5-1	Director	Grant A	4.4K	+12%	—	$0
May 13, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$78.16	$39.1K
May 13, 2026	Patrick D Walsh	Director	Sell S	10.0K	-21%	$80.63	$806.3K
May 12, 2026	Ori Gutwerg	SVP, GENERICS	Sell S	2.8K	-3%	$79.50	$220.4K
May 12, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Sell S	459	-1%	$79.21	$36.4K
May 11, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Sell S	55.0K	-14%	$77.57	$4.3M
May 11, 2026	Patrick D Walsh	Director	Sell S	4.0K	-8%	$80.75	$320.8K
Apr 13, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$77.95	$39.0K
Mar 13, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$72.62	$36.3K
Mar 13, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	3.2K	-3%	$71.64	$226.5K
Mar 11, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Sell S	4.8K	-11%	$74.91	$357.5K
Mar 9, 2026	Krista Davis 10b5-1	SVP, CHIEF HR OFFICER	Sell S	5.1K	-9%	$74.13	$377.1K
Mar 9, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	3.6K	-4%	$74.18	$267.2K
Mar 7, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Other F	3.3K	-3%	$74.04	$245.4K
Mar 7, 2026	Ori Gutwerg	SVP, GENERICS	Other F	3.3K	-4%	$74.04	$245.4K
Mar 7, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Other F	17.1K	-4%	$74.04	$1.3M
Mar 7, 2026	Stephen P. Carey KEY	SVP & CFO	Other F	5.2K	-3%	$74.04	$381.3K
Mar 6, 2026	Krista Davis 10b5-1	SVP, CHIEF HR OFFICER	Sell S	1.5K	-3%	$75.00	$111.4K
Mar 6, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	2.1K	-2%	$74.22	$157.4K
Mar 5, 2026	Stephen P. Carey KEY	SVP & CFO	Exercise M	3.3K	+50%	$49.51	$164.0K
Mar 5, 2026	Stephen P. Carey KEY	SVP & CFO	Sell S	4.0K	-2%	$75.56	$302.2K
Mar 5, 2026	Stephen P. Carey KEY	SVP & CFO	Sell S	3.3K	-2%	$75.42	$249.8K
Mar 5, 2026	Stephen P. Carey KEY	SVP & CFO	Exercise M	3.3K	+2%	$49.51	$164.0K
Mar 3, 2026	Patrick D Walsh	Director	Sell S	6.0K	-10%	$74.23	$445.4K
Mar 3, 2026	Ori Gutwerg	SVP, GENERICS	Sell S	2.1K	-2%	$76.50	$157.6K
Mar 2, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	417	-0%	$74.00	$30.9K
Feb 28, 2026	Krista Davis	SVP, CHIEF HR OFFICER	Other F	1.6K	-3%	$73.90	$114.9K
Feb 28, 2026	Meredith Cook	SR. VP, GENERAL COUNSEL & SEC.	Other F	1.6K	-2%	$73.90	$114.9K
Feb 28, 2026	Chad Gassert	SVP - CORP. DEV. & STRATEGY	Other F	2.2K	-3%	$73.90	$164.1K
Feb 28, 2026	Christopher Mutz	HEAD OF RARE DISEASE	Other F	2.2K	-2%	$73.90	$164.1K
Feb 28, 2026	Ori Gutwerg	SVP, GENERICS	Other F	2.2K	-2%	$73.90	$164.1K
Feb 28, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Other F	12.2K	-3%	$73.90	$902.8K
Feb 28, 2026	Stephen P. Carey KEY	SVP & CFO	Other F	2.8K	-1%	$73.90	$204.9K
Feb 28, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Other F	628	-1%	$73.90	$46.4K
Feb 26, 2026	Krista Davis	SVP, CHIEF HR OFFICER	Grant A	10.8K	+22%	$77.15	$834.0K
Feb 26, 2026	Meredith Cook	SR. VP, GENERAL COUNSEL & SEC.	Grant A	13.9K	+21%	$77.15	$1.1M
Feb 26, 2026	Chad Gassert	SVP - CORP. DEV. & STRATEGY	Grant A	11.1K	+17%	$77.15	$857.6K
Feb 26, 2026	Muthusamy Shanmugam	HEAD OF R&D, COO-NOVITIUM OPS	Grant A	11.1K	+12%	$77.15	$857.6K
Feb 26, 2026	Christopher Mutz	HEAD OF RARE DISEASE	Grant A	21.3K	+25%	$77.15	$1.6M
Feb 26, 2026	Ori Gutwerg	SVP, GENERICS	Grant A	13.0K	+17%	$77.15	$1.0M
Feb 26, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Grant A	75.6K	+21%	$77.15	$5.8M
Feb 26, 2026	Stephen P. Carey KEY	SVP & CFO	Grant A	22.2K	+13%	$77.15	$1.7M
Feb 26, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Grant A	6.0K	+16%	$77.15	$464.5K
Feb 20, 2026	Krista Davis 10b5-1	SVP, CHIEF HR OFFICER	Sell S	1.7K	-3%	$77.99	$134.9K
Feb 20, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	5.3K	-6%	$78.02	$415.3K
Feb 19, 2026	Krista Davis 10b5-1	SVP, CHIEF HR OFFICER	Sell S	2.1K	-4%	$77.53	$161.6K
Feb 14, 2026	Krista Davis	SVP, CHIEF HR OFFICER	Other F	1.3K	-2%	$77.36	$99.8K
Feb 14, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Other F	1.8K	-3%	$77.36	$137.6K
Feb 14, 2026	Chad Gassert	SVP - CORP. DEV. & STRATEGY	Other F	1.7K	-3%	$77.36	$132.8K
Feb 14, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Other F	2.4K	-3%	$77.36	$185.9K
Feb 14, 2026	Ori Gutwerg	SVP, GENERICS	Other F	1.9K	-2%	$77.36	$146.1K
Feb 14, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Other F	10.3K	-3%	$77.36	$796.7K
Feb 14, 2026	Stephen P. Carey KEY	SVP & CFO	Other F	2.4K	-1%	$77.36	$189.4K
Feb 14, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Other F	485	-1%	$77.36	$37.5K
Feb 13, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$76.80	$38.4K
Feb 12, 2026	Krista Davis	SVP, CHIEF HR OFFICER	Other F	1.2K	-2%	$76.70	$90.5K
Feb 12, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Other F	1.5K	-2%	$76.70	$117.7K
Feb 12, 2026	Chad Gassert	SVP - CORP. DEV. & STRATEGY	Other F	1.6K	-2%	$76.70	$123.3K
Feb 12, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Sell S	7.0K	-7%	$76.55	$538.3K
Feb 12, 2026	Christopher Mutz 10b5-1	HEAD OF RARE DISEASE	Other F	3.2K	-3%	$76.70	$243.4K
Feb 12, 2026	Ori Gutwerg	SVP, GENERICS	Other F	1.8K	-2%	$76.70	$136.1K
Feb 12, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Other F	11.7K	-3%	$76.70	$896.5K
Feb 12, 2026	Stephen P. Carey KEY	SVP & CFO	Other F	2.8K	-2%	$76.70	$217.0K
Feb 12, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Other F	566	-1%	$76.70	$43.4K
Feb 11, 2026	Krista Davis	SVP, CHIEF HR OFFICER	Other F	3.0K	-5%	$76.25	$230.0K
Feb 11, 2026	Meredith Cook	SR. VP, GENERAL COUNSEL & SEC.	Other F	3.0K	-4%	$76.25	$229.6K
Feb 11, 2026	Chad Gassert	SVP - CORP. DEV. & STRATEGY	Other F	4.3K	-6%	$76.25	$325.5K
Feb 11, 2026	Muthusamy Shanmugam	HEAD OF R&D, COO-NOVITIUM OPS	Other F	2.9K	-3%	$76.25	$221.0K
Feb 11, 2026	Christopher Mutz	HEAD OF RARE DISEASE	Other F	4.5K	-4%	$76.25	$346.6K
Feb 11, 2026	Ori Gutwerg	SVP, GENERICS	Other F	4.3K	-5%	$76.25	$325.4K
Feb 11, 2026	Nikhil Lalwani KEY	PRESIDENT & CEO	Other F	30.7K	-7%	$76.25	$2.3M
Feb 11, 2026	Stephen P. Carey KEY	SVP & CFO	Other F	5.5K	-3%	$76.25	$419.6K
Feb 11, 2026	Thomas Andrew Rowland	SVP, HEAD - ESTABLISHED BRANDS	Other F	1.8K	-4%	$76.25	$134.4K
Jan 13, 2026	Meredith Cook 10b5-1	SR. VP, GENERAL COUNSEL & SEC.	Sell S	500	-1%	$84.33	$42.2K

About ANIP insider trading

This page tracks insider transactions for ANI PHARMACEUTICALS INC (ANIP) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.